549 Modern Skincare
region of interest by a Canfield research device under UV-fluorescence or red-light modalities.
Finally, the three participants had their skin swabbed (5 samples per participant), which was
tested for relative levels of skin bacterial groups via 16S rRNA sequencing.61
REFERENCES
(1) Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011 9(4):244–253. doi:10.1038/
nrmicro2537
(2) Fournière M, Latire T, Souak D, Feuilloley MGJ, Bedoux G. Staphylococcus epidermidis and Cutibacterium
acnes: two Major Sentinels of Skin microbiota and the Influence of Cosmetics. Microorganisms. 2020 8(11).
doi:10.3390/microorganisms8111752
(3) Brüggemann H, Salar-Vidal L, Gollnick HPM, Lood R. A Janus-faced Bacterium: Host-Beneficial
and -Detrimental Roles of Cutibacterium acnes. Front Microbiol. 2021 12:673845. doi:10.3389/
fmicb.2021.673845
(4) Zheng Y, Hunt RL, Villaruz AE, et al. Commensal Staphylococcus epidermidis contributes to skin
barrier homeostasis by generating protective ceramides. Cell Host Microbe. 2022 30(3):301–313.e9.
doi:10.1016/j.chom.2022.01.004
(5) Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human skin
microbiome. Science. 2009 324(5931):1190–1192. doi:10.1126/science.1171700
(6) Oh J, Byrd AL, Park M, NISC Comparative Sequencing Program, Kong HH, Segre JA. Temporal
stability of the human skin microbiome. Cell. 2016 165(4):854–866. doi:10.1016/j.cell.2016.04.008
(7) Coenye T, Peeters E, Nelis HJ. Biofilm formation by Propionibacterium acnes is associated with increased
resistance to antimicrobial agents and increased production of putative virulence factors. Res Microbiol.
2007 158(4):386–392. doi:10.1016/j.resmic.2007.02.001
(8) Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep.
2015 15(11):65. doi:10.1007/s11882-015-0567-4
(9) Koh LF, Ong RY, Common JE. Skin microbiome of atopic dermatitis. Allergol Int. 2022 71(1):31–39.
doi:10.1016/j.alit.2021.11.001
(10) Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012 379(9813):361–372. doi:10.1016/
S0140-6736(11)60321-8
(11) Fitz-Gibbon S, Tomida S, Chiu B-H, et al. Propionibacterium acnes strain populations in the human
skin microbiome associated with acne. J Invest Dermatol. 2013 133(9):2152–2160. doi:10.1038/jid.2013.21
(12) Kinney MA, Yentzer BA, Fleischer AB, Feldman SR. Trends in the treatment of acne vulgaris: are
measures being taken to avoid antimicrobial resistance? J Drugs Dermatol. 2010 9(5):519–524.
(13) Uhlenhake E, Yentzer BA, Feldman SR. Acne vulgaris and depression: a retrospective examination. J
Cosmet Dermatol. 2010 9(1):59–63. doi:10.1111/j.1473-2165.2010.00478.x
(14) Yentzer BA, Hick J, Reese EL, Uhas A, Feldman SR, Balkrishnan R. Acne vulgaris in the United States:
a descriptive epidemiology. Cutis. 2010 86(2):94–99.
(15) Li ZJ, Choi DK, Sohn KC, et al. Propionibacterium acnes activates the NLRP3 inflammasome in human
sebocytes. J Invest Dermatol. 2014 134(11):2747–2756. doi:10.1038/jid.2014.221
(16) Woese CR, Fox GE. Phylogenetic structure of the prokaryotic domain: the primary kingdoms. Proc Natl
Acad Sci U S A. 1977 74(11):5088–5090. doi:10.1073/pnas.74.11.5088
(17) Grice EA. The skin microbiome: potential for novel diagnostic and therapeutic approaches to cutaneous
disease. Semin Cutan Med Surg. 2014 33(2):98–103. doi:10.12788/j.sder.0087
(18) Grice EA. The intersection of microbiome and host at the skin interface: genomic- and metagenomic-
based insights. Genome Res. 2015 25(10):1514–1520. doi:10.1101/gr.191320.115
(19) Jamal M, Bukhari SMAUS, Andleeb S, et al. Bacteriophages: an overview of the control strategies against
multiple bacterial infections in different fields. J Basic Microbiol. 2019 59(2):123–133. doi:10.1002/
jobm.201800412

550 JOURNAL OF COSMETIC SCIENCE
(20) Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: A renewed approach to combat antibiotic-
resistant bacteria. Cell Host Microbe. 2019 25(2):219–232. doi:10.1016/j.chom.2019.01.014
(21) Letarov AV. History of early bacteriophage research and emergence of key concepts in virology.
Biochemistry (Mosc). 2020 85(9):1093–1010. doi:10.1134/S0006297920090096
(22) Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug
resistance. World J Gastrointest Pharmacol Ther. 2017 8(3):162–173. doi:10.4292/wjgpt.v8.i3.162
(23) Bertozzi Silva J, Storms Z, Sauvageau D, hosts. Host receptors for bacteriophage adsorption. FEMS
Microbiol Lett. 2016 363(4). doi:10.1093/femsle/fnw002
(24) Ge H, Hu M, Zhao G, et al. The ‘fighting wisdom and bravery’ of tailed phage and host in the process
of adsorption. Microbiol Res. 2020 230:126344. doi:10.1016/j.micres.2019.126344
(25) Sharma S, Chatterjee S, Datta S, et al. Bacteriophages and its applications: an overview. Folia Microbiol
(Praha). 2017 62(1):17–55. doi:10.1007/s12223-016-0471-x
(26) Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage. 2011 1(1):31–45.
doi:10.4161/bact.1.1.14942
(27) Hatfull GF, Hendrix RW. Bacteriophages and their genomes. Curr Opin Virol. 2011 1(4):298–303.
doi:10.1016/j.coviro.2011.06.009
(28) Suttle CA. Viruses in the sea. Nature. 2005 437(7057):356–361. doi:10.1038/nature04160
(29) Aswani VH, Shukla SK. An early history of phage therapy in the United States: is it time to reconsider?
Clin Med Res. 2021 19(2):82–89. doi:10.3121/cmr.2021.1605
(30) Marongiu L, Burkard M, Lauer UM, Hoelzle LE, Venturelli S. Reassessment of historical clinical trials supports
the effectiveness of phage therapy. Clin Microbiol Rev. 2022 35(4):e0006222. doi:10.1128/cmr.00062-22
(31) Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother.
2001 45(3):649–659. doi:10.1128/AAC.45.3.649-659.2001
(32) Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage.
2011 1(2):66–85. doi:10.4161/bact.1.2.15845
(33) d’Herelle F. Bacteriophage as a treatment in acute medical and surgical infections. Bull N Y Acad Med.
1931 7(5):329-348.
(34) Fathima B, Archer AC. Bacteriophage therapy: recent developments and applications of a renaissant
weapon. Res Microbiol. 2021 172(6):103863. doi:10.1016/j.resmic.2021.103863
(35) Hannigan GD, Meisel JS, Tyldsley AS, et al. The human skin double-stranded DNA virome: topographical
and temporal diversity, genetic enrichment, and dynamic associations with the host microbiome. mBio.
2015 6(5):e01578-e01515. doi:10.1128/mBio.01578-15
(36) Oh J, Byrd AL, Deming C, et al. Biogeography and individuality shape function in the human skin
metagenome. Nature. 2014 514(7520):59–64. doi:10.1038/nature13786
(37) Wang H, Chan HH, Ni MY, Lam WW, Chan WMM, Pang H. Bacteriophage of the skin microbiome
in patients with psoriasis and healthy family controls. J Invest Dermatol. 2020 140(1):182-190.e5.
doi:10.1016/j.jid.2019.05.023
(38) Wielscher M, Pfisterer K, Samardzic D, et al. The phageome in normal and inflamed human skin. Sci
Adv. 2023 9(39):eadg4015. doi:10.1126/sciadv.adg4015
(39) Natarelli N, Gahoonia N, Sivamani RK. Bacteriophages and the microbiome in dermatology: the role of
the phageome and a potential therapeutic strategy. Int J Mol Sci. 2023 24(3). doi:10.3390/ijms24032695
(40) Brown TL, Petrovski S, Dyson ZA, Seviour R, Tucci J. The formulation of bacteriophage in a semi
solid preparation for control of Propionibacterium acnes growth. PLOS ONE. 2016 11(3):e0151184.
doi:10.1371/journal.pone.0151184
(41) Marinelli LJ, Fitz-Gibbon S, Hayes C, et al. Propionibacterium acnes bacteriophages display limited
genetic diversity and broad killing activity against bacterial skin isolates. mBio. 2012 3(5). doi:10.1128/
mBio.00279-12
(42) Rimon A, Rakov C, Lerer V, et al. Topical phage therapy in a mouse model of Cutibacterium acnes-
induced acne-like lesions. Nat Commun. 2023 14(1):1005. doi:10.1038/s41467-023-36694-8